Skip to main content
Equibles

Limestone Investment Advisors LP

Position in NVO — Novo Nordisk A S

CIK 2075597 NEW YORK, NY
Back to NVO Full portfolio

Position in NVO

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$1,396,492
-$680,250 QoQ
Shares Held
29,130
-48.5% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.72%
of 13F equity value
Holder Rank
#443
of 1,348 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in NVO Over Time

Shares Held

Position Value (USD)

Derivatives in NVO

reported options exposure · as of Jun 30, 2026
CallValue
$3,034,602
CallShares
63,300
PutValue
$2,238,798
PutShares
46,700

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

Limestone Investment Advisors LP holds $1,815,578 across 3 Drug Manufacturers - General names. NVO ranks #1 (76.9% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 NVO
Novo Nordisk A S
This page 		29,130 $1,396,492
2 GILD
Gilead Sciences, Inc.
 2,620 $331,010
3 NVS
Novartis AG
 562 $88,076

All Filings in NVO

Export CSV
15 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,238,798 46,700
2026-06-30 $3,034,602 63,300
2026-06-30 $1,396,492 29,130
2026-03-31 $2,076,742 56,510
2026-03-31 $4,277,700 116,400
2026-03-31 $4,082,925 111,100
2025-12-31 $1,311,533 25,777
2025-12-31 $3,429,312 67,400
2025-12-31 $3,169,824 62,300
2025-09-30 $144,274 2,600
2025-09-30 $604,841 10,900
2025-09-30 $2,097,133 37,793
2025-06-30 $648,788 9,400
2025-06-30 $1,076,228 15,593
2025-06-30 $579,768 8,400

Report a Problem

Category
Description
Email (optional, for follow-up)